In the team’s study, 84% of subjects experienced significant improvement on several measures of cognition, including MoCA, CNS Vital Signs, Brain HQ, AQ-21, and AQ-C. What makes ReCODE so successful? Instead of predetermining a single pharmaceutical treatment, ReCODE identifies and targets the root causes of cognitive decline for each person. These assessed potential contributors include inflammation, insulin resistance, nutritional and hormonal deficiencies, specific pathogens, toxics and biotoxins, and genetics. This process has led to unprecedented results. In addition to 84% of patients experiencing cognitive improvement, improvements in symptoms and gray matter volumes on MRI were also reported.
While most scientific breakthroughs take decades to hit the market, ReCODE is ready to help people quickly, as it is already available to consumers through Apollo Health. There are qualified practitioners in almost every state and in many international locations.
After hundreds of unsuccessful trials in Alzheimer’s disease and a few pharmaceutical options (like donanemab and aducanumab) that have only slowed the decline, the ReCODE protocol represents a giant leap in treatment and can finally provide relief to people with dementia.
SOURCE Apollo Health